Rutgers is the only site in the United States for the study, called Triple Combination Antiviral Coronavirus Therapy (TriACT).
To be eligible, patients must have been diagnosed with COVID-19 within the previous six days, and preferably within the last two days. Referrals may come from physicians or patients. For more information, call 833-874-2281 (1-833-TRIACT1), email triact@rwjms.rutgers.edu or visit www.triact1.com. Read the Full Story.